A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients

Clinical Cancer Research

Volumn 20, Issue 14, 2014, Pages 3660-3671

  Alfonso, Sailyn ^a   Valdés Zayas, Anet ^b   Santiesteban, Eduardo R ^c   Flores, Yoanna I ^d   Areces, Fernando ^d   Hernández, Maurenis ^b   Viada, Carmen E ^b   Mendoza, Ivis C ^a   Guerra, Pedro P ^a   García, Elena ^a   Ortiz, Ramón A ^a   De La Torre, Ana V ^a   Cepeda, Meylán ^a   Pérez, Kirenia ^b   Chong, Eric ^b   Hernández, Ana María ^b   Toledo, Darien ^b   González, Zuyén ^b   Mazorra, Zaima ^b   Crombet, Tania ^b   Pérez, Rolando ^b   Vázquez, Ana María ^b   Macías, Amparo E ^b   more..

^a Celestino Hernández Robau Hospital ^*  (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c José R López Tabranes Hospital   (Cuba)

^d INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; PLACEBO; RACOTUMOMAB; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; CANCER VACCINE; GANGLIOSIDE GM3; MONOCLONAL ANTIBODY; N-GLYCOLYLNEURAMINYLLACTOSYLCERAMIDE;

ADULT; ADVANCED CANCER; ANOREXIA; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DYSPNEA; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE BURNING; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN INDURATION; SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; G(M3) GANGLIOSIDE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PLACEBOS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 84904386095     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1674     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Minna JD. Neoplasmas of the lung. In:Kasper AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. New York: McGraw-Hill; 2005. p. 506-16.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. (Pubitemid 34438899)
4. Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, Cappuzzo F, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012;76:269-79.
5. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-63.
6. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40.
7. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-8.
8. Miller VA, O'Connor P, Soh C, Kabbinavar FF. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:18s, 2009 (suppl; abstr LBA8002).
9. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
10. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753-60.
11. Kabbinavar FF, Miller VA, Johnson BE, O'Connor PG, Soh C. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28:15s, 2010 (suppl; abstr 7526).
12. Zhang L, Shenglin M, Song X, Han B, Cheng Y, Huang C, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). J Clin Oncol 29:15s, 2011 (suppl; abstr LBA7511).
13. Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:3516-24.
14. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pempluscisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 30, 2012 (suppl; abstr LBA7507).
15. Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a randomized phase III study in advanced non-small cell lung cancer. J Clin Oncol 27:18s, 2009 (suppl; abstr CRA8000).
16. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998;4:1117-24. (Pubitemid 28213321)
17. Chapman PB. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 2003;4:710-5. (Pubitemid 36916712)
18. Irie A, Suzuki A. CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem Biophys Res Commun 1998;248:330-3. (Pubitemid 28386421)
19. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 1998;273:15866-71. (Pubitemid 28298210)
20. Olson MV, Varki A. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 2003;4:20-8. (Pubitemid 36043212)
21. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996;56:5165-71. (Pubitemid 26383031)
22. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 2009;9:180.
23. Blanco R, Rengifo CE, Cedeno M, Frometa M, Rengifo E, Carr A. Immunoreactivity of the 14F7 mAb (raised against N-glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer. Patholog Res Int 2012;2012:235418.
24. Hayashi N, Chiba H, Kuronuma K, Go S, Hasegawa Y, Takahashi M, et al. Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody. Cancer Sci 2013;104:43-7.
25. de Leon J, Fernandez A, Mesa C, Clavel M, Fernandez LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006;55:443-50. (Pubitemid 43076896)
26. Vazquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, et al. Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998;17:527-34. (Pubitemid 29024638)
27. Vazquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995;14:551-6. (Pubitemid 26028517)
28. Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002;168:2523-9. (Pubitemid 34171859)
29. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007;6:145-50. (Pubitemid 46641614)
30. Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Perez K, et al. 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 2007;6:1847-52. (Pubitemid 351590395)
31. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009;58:1117-28.
32. Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003;107:80-9. (Pubitemid 36579371)
33. Hernandez AM, Toledo D, Martinez D, Grinan T, Brito V, Macias A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008;181:6625-34.
34. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, et al. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 2006;29:215-23.
35. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
36. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
37. Stults CL, Sweeley CC, Macher BA. Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 1989;179:167-214. (Pubitemid 20044395)
38. Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008;7:2033-41.
39. Rodriguez-Zhurbenko N, Martinez D, Blanco R, Rondon T, Grinan T, Hernandez AM. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur J Immunol 2013;43:826-37.
40. Fernandez-Marrero Y, Hernandez T, Roque-Navarro L, Talavera A, Moreno E, Grinan T, et al. Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Mol Immunol 2011;48:1059-67.
41. Hernandez AM, Rodriguez N, Gonzalez JE, Reyes E, Rondon T, Grinan T, et al. Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol 2011;186:3735-44.
42. Giaccone G, Bazhenova L, Nemunaitis N, Juhasz E, Ramlau R, van den Heuvel MM, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer. European Cancer Congress, 2013 (suppl; abstr LBA 2).
43. Butts C, Socinski MA, Mitchell P, Thatcher N, Havel L, Krzakowski M, et al. START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J Clin Oncol 31, 2013 (suppl; abstr 7500).
44. Crombet T, Neninger E, Acosta S, Amador R, Mendoza S, Santiesteban E, et al. EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial. J Clin Oncol 30, 2012 (suppl; abstr 2527).
45. Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1995;6:357-66.
46. Yao TJ, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999;5:77-81. (Pubitemid 29045180)
47. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A 2003;100:12045-50. (Pubitemid 37271512)
48. Yin J, Hashimoto A, Izawa M, Miyazaki K, Chen GY, Takematsu H, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 2006;66:2937-45.
49. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, et al. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 2003;21:1601-12. (Pubitemid 36287592)